RE:RE:Breast cancer treatment: perspectives on the oncolytic virusPatholgists have recently made recommendations to include TILs in the pathology reports of early-stage TNBC worldwide, as it has the potential to inform clinicians and patients when they discuss treatment options.
This biomarker would only require a visual evaluation by a pathologist looking through a microscope, meaning there are no additional costs associated with identifying the presence of immune cells. This could be particularly beneficial to regions with limited resources, said Dr. Leon-Ferre, breast medical oncologist at Mayo Clinic Comprehensive Cancer Center and first author of the study recommending TiLs as an available biomarker to most all pathologists.
ONCY has identified TiLs as a biomarker and has demonstrated pelareorep's ability to enhance levels of TILS in the tumor microenvironment (TME) thus facilitating the killing of cancer cells including those in TNBC.